AAV Factor I Gene Therapy for Complement Control in Dry AMD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for age-related macular degeneration (AMD), particularly dry AMD, are inadequate as they do not effectively address the underlying complement system dysregulation, leading to progressive vision loss and geographic atrophy.
Innovation Solution
Delivering Factor I, Factor H, or anti-complement component antibodies via adeno-associated viral (AAV) vectors to modulate the complement C3b feedback cycle, thereby regulating C3b and iC3b breakdown to reduce inflammation and prevent geographic atrophy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for AMD are used, then they are simple to administer, but they fail to effectively address complement system dysregulation leading to progressive vision loss
Solution Approach 1:
The patent uses AAV vectors as intermediaries to deliver complement regulatory proteins (Factor H, Factor I, MCP) directly to retinal cells. These vectors mediate the transfer of therapeutic genes from external administration to intracellular expression, enabling sustained production of complement-regulating proteins that directly address the underlying pathogenesis of AMD while maintaining a relatively simple administration route.
Solution Approach 2:
The therapeutic approach enables retinal cells to self-produce complement regulatory proteins through gene therapy. Once the AAV vector delivers the therapeutic gene, the host cells continuously express the complement regulatory protein autonomously, providing long-term protection against complement-mediated damage without requiring repeated administrations of the actual therapeutic protein.
2Reliability
If AAV vectors delivering complement regulatory proteins are used, then C3b-inactivating and iC3b-degradation activity increases, but the treatment complexity increases
Solution Approach 1:
The patent achieves localized overexpression of complement regulatory proteins specifically in retinal tissue where they are most needed. The AAV vectors are administered directly into the eye and preferentially transduce retinal cells, creating a localized high concentration of therapeutic protein exactly where complement dysregulation causes damage, while avoiding systemic distribution and reducing off-target effects.
Solution Approach 2:
The gene therapy approach performs preliminary action by establishing permanent genetic expression of complement regulatory proteins before complement-mediated damage can progress. The AAV vector delivers the therapeutic gene in advance, enabling the retinal cells to continuously produce protective proteins that prevent future complement attacks rather than treating damage after it occurs.
3Duration of action of stationary object
If gene therapy with AAV vectors is administered, then long-term protection against geographic atrophy is achieved, but the administration procedure becomes more complex
Solution Approach 1:
The AAV vector establishes continuous expression of complement regulatory proteins in retinal cells, providing uninterrupted protection against complement-mediated geographic atrophy. Unlike protein replacement therapy that requires repeated injections, the gene therapy creates a self-sustaining system where the host cells continuously produce the therapeutic protein, maintaining protective levels indefinitely after a single administration.
Solution Approach 2:
The AAV vector serves as a permanent intermediary that bridges external administration and internal continuous production. The viral vector integrates or maintains the therapeutic gene in host cells, acting as a self-replicating factory that continuously produces the complement regulatory protein without requiring further external intervention, thus simplifying long-term management despite the complexity of initial vector administration.
Data Source
AI summary
An AAV vector comprising a nucleotide sequence encoding Factor I or a fragment or derivative thereof.